Pfizer Vaccine: What Are The Hurdles Ahead?
Dale Fisher, Professor of Infectious Diseases, National University of Singapore
11-Nov-20 07:37
Embed Podcast
You can share this podcast by copying this HTML to your clipboard and pasting into your blog or web page.
Close
We’re one step closer to getting a Covid-19 vaccine, but on the back of this positive news, what concerns should we be paying attention to?
The Pfizer and BioNTech team have announced that the vaccine they’re developing is 90% effective in protecting people from the transmission of the Covid-19 virus in global trials.
Based on the interim analysis, which will continue till December, the vaccine has performed better than expected, with no safety concerns to report so far.
Pfizer and BioNTech are looking at globally supplying up to 50 million vaccine doses in 2020, and up to 1.3 billion doses in 2021.
There’s no doubt that this is good news, but the public has been advised to be cautiously optimistic as full data is not available yet and that the trials are ongoing.
Image Credit: Shutterstock
Produced by: Arleen Webber
Presented by: Roshan Kanesan, Wong Shou Ning
This and more than 60,000 other podcasts in your hand. Download the all new BFM mobile app.
Categories: Politics, Law and Legal Matters, Health Policy, Diseases and Conditions, Mental Health, Healthy Living, Fitness, Science, Business Analysis, Trends and Forecasts, Markets, Social Issues, Medical Innovation and Technology, Investments
Tags: covid-19, vaccine, pfizer, bioNtech,
